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Cambodia’s first-line artemisinin combination therapy, dihydroartemisinin-piperaquine (DHA-PPQ), is no longer sufficiently cura-
tive against multidrug-resistant Plasmodium falciparum malaria at some Thai-Cambodian border regions. We report recent
(2008 to 2013) drug resistance trends in 753 isolates from northern, western, and southern Cambodia by surveying for ex vivo
drug susceptibility and molecular drug resistance markers to guide the selection of an effective alternative to DHA-PPQ. Over
the last 3 study years, PPQ susceptibility declined dramatically (geomean 50% inhibitory concentration [IC50] increased from
12.8 to 29.6 nM), while mefloquine (MQ) sensitivity doubled (67.1 to 26 nM) in northern Cambodia. These changes in drug sus-
ceptibility were significantly associated with a decreased prevalence of P. falciparum multidrug resistance 1 gene (Pfmdr1) mul-
tiple copy isolates and coincided with the timing of replacing artesunate-mefloquine (AS-MQ) with DHA-PPQ as the first-line
therapy. Widespread chloroquine resistance was suggested by all isolates being of the P. falciparum chloroquine resistance
transporter gene CVIET haplotype. Nearly all isolates collected from the most recent years had P. falciparum kelch13 mutations,
indicative of artemisinin resistance. Ex vivo bioassay measurements of antimalarial activity in plasma indicated 20% of patients
recently took antimalarials, and their plasma had activity (median of 49.8 nM DHA equivalents) suggestive of substantial in vivo
drug pressure. Overall, our findings suggest DHA-PPQ failures are associated with emerging PPQ resistance in a background of
artemisinin resistance. The observed connection between drug policy changes and significant reduction in PPQ susceptibility
with mitigation of MQ resistance supports reintroduction of AS-MQ, in conjunction with monitoring of the P. falciparum mdr1
copy number, as a stop-gap measure in areas of DHA-PPQ failure.
Amajor obstacle to the success of malaria control and elimina-tion efforts is the emergence and spread of drug-resistant ma-
laria. Southeast Asia, especially along the Thai-Cambodia and
Thai-Myanmar borders, appears to be the epicenter of the global
emergence of multidrug-resistant malaria, where chloroquine re-
sistance was first reported in the late 1950s, followed by resistance
to sulfadoxine-pyrimethamine in the mid-1960s and mefloquine
in the late 1980s (1–4). In response to this growing problem of
drug resistance, the World Health Organization (WHO) since
2000 has recommended the use of artemisinin-based combination
therapies (ACTs) in which a fast-acting artemisinin-based drug is
paired with a slower-acting drug from another chemical class that
acts against the parasite using a different mechanism of action. In
2000 in Cambodia, the ACT artesunate-mefloquine (AS-MQ) re-
placed MQ monotherapy as the first-line treatment of P. falcipa-
rum malaria (5). AS-MQ was replaced with dihydroartemisinin-
piperaquine (DHA-PPQ) as the drug of choice to address
concerns associated with increasing evidence of AS-MQ treatment
failures (6). This drug policy change initially was implemented in
2008 in western Cambodia; in 2012, DHA-piperaquine was ad-
opted nationally as the first-line drug of choice following more
widespread reports of AS-MQ failure. More recently, reports of
treatment failures with DHA-PPQ have been increasing, suggest-
ing that this ACT is failing in western Cambodia (7, 8). Further-
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more, we recently found the standard 3-day dosing regimen of
DHA-PPQ also is failing in northern Cambodia, showing a higher
failure rate than that observed in an earlier trial conducted at the
same site only 3 years prior (42-day-per-protocol efficacy for P.
falciparum monoinfections of 79% in 2010 versus only 47% in
2013) (9, 10). While it remains to be definitively determined
whether resistance to artemisinins or PPQ (or a combination of
both) is contributing to DHA-PPQ failures, these findings are
alarming and demand careful drug resistance monitoring to in-
form appropriate public health policy to address this crisis.
Ex vivo drug sensitivity testing of fresh clinical isolates is an
effective means for active surveillance and tracking of emerging
drug resistance. Ex vivo screening provides results reflecting the
overall drug susceptibility phenotype of an in vivo infection by
avoiding clonal selection during culture adaptation (11, 12). We
employ the histidine-rich protein-2 (HRP-2) enzyme-linked im-
munosorbent assay (ELISA) as a nonradioactive, highly sensitive
ex vivo assay to determine the susceptibility of P. falciparum iso-
lates of relatively low parasitemia against a standard panel of com-
mon drugs (13–15). Using the HRP-2 ELISA in our drug resis-
tance surveillance efforts, we reported the progressive decline of P.
falciparum susceptibility to artemisinins and other standard drugs
in western Cambodia during 2006 to 2010 (14). The drug resis-
tance trends found using the HRP-2 assay corresponded with clin-
ical reports of delayed parasite clearance time of ACTs in this
region during this time (8) and are similar to findings reported by
another drug resistance surveillance study conducted in Cambo-
dia during 2001 to 2007 using the [3H]hypoxanthine assay (16). In
addition to being a useful drug resistance monitoring tool, the
HRP-2 assay also was used recently to assess the activity of malaria
drug candidates against P. falciparum multidrug-resistant parasite
populations in Cambodia (17). Here, we describe the results of ex
vivo drug susceptibility phenotypic and genotypic characteriza-
tion of 753 P. falciparum clinical isolates collected from western,
northern, and southern Cambodia in 2008 to 2013 to further de-
fine temporal and geographical trends in malaria drug resistance
emergence and spread.
MATERIALS AND METHODS
Studies sites, protocols, and subjects. P. falciparum clinical isolates were
collected from patients with uncomplicated malaria from multiple prov-
inces during August 2008 to November 2013 in western (Pailin and
Battambang), northern (Preah Vihear and Oddar Mean Chey), and
southern (Kampong Speu, Preah Sihanouk, Kampot, and Koh Kong)
Cambodia (Fig. 1). Isolates were collected through 4 clinical protocols
(clinical trials WR1396 [NCT00722150]; WR1737 [NCT01280162];
WR1877 [NCT01849640]; and WR1576, an in vitro surveillance study),
all approved by the Cambodian National Ethics Committee for Health
Research (NECHR) and the Walter Reed Army Institute of Research
(WRAIR) Institutional Review Board. All study subjects provided in-
formed consent prior to participation, and all clinical trial protocols com-
plied with International Conference on Harmonization Good Clinical
Practice (ICH-GCP) guidelines. Study volunteer inclusion criteria in-
cluded age 18 to 65 years (13 to 65 years for WR1576) and no history of
antimalarial use within the preceding 7 days for WR1576, 30 days for
FIG 1 Cambodian field sites and numbers of P. falciparum isolates by region collected from malaria patients during 2008 to 2013. The map shows the locations
of isolate collection sites (dot patterns denote collection provinces; gray, pink, and green shading indicate western, northern, and southern regional district areas,
respectively; a plus sign indicates health centers). The table presents numbers of isolates collected per site per year and totals by region.
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WR1396, or 28 days for WR1877. In all studies, subjects were excluded if
there were signs or symptoms of severe malaria, history of allergy or con-
traindication to study drug (if any), family history of sudden cardiac death
or clinically significant electrocardiographic abnormality (WR1737 and
WR1877), or conditions judged by the investigator to be unsuitable for
study participation.
Malaria microscopy. Two microscopists examined Giemsa-stained
peripheral blood smears for each volunteer to determine malaria species
infection and parasite densities for asexual and gametocyte stages. All slide
readings were performed using thick smears, unless there were 500 par-
asites/200 white blood cells (WBCs), in which case thin smears were read
instead. Discrepancies in species diagnosis between microscopists were
resolved in real time by a third reader, who determined the final result.
Parasite density (parasites/microliter) was calculated based on the num-
ber of parasites/200 WBCs in the thick smear or the number of parasites/
5,000 RBCs in the thin smear. Patients were considered negative for ma-
laria blood-stage infection when no parasites were found in 200 oil
immersion fields on thick-smear examination.
Sample collection and preparation. At the time of diagnosis (before
malaria treatment), venous blood samples were collected in sodium hep-
arin tubes for ex vivo P. falciparum drug susceptibility testing and the ex
vivo bioassay measuring preexisting antimalarial activity in plasma. For
drug susceptibility testing, samples were transported on ice (2 to 8°C) and
applied to dried drug plates within 6 h after phlebotomy, without a leu-
kocyte depletion step or culture adaptation, as previously described (14).
For the P. falciparum ex vivo bioassay, plasma was separated from blood,
frozen at 20°C, and transported to the Armed Forces Research Institute
of Medical Science (AFRIMS) for analysis. Additional blood samples were
collected in EDTA, frozen at 20°C, and transported to AFRIMS for
preparing genomic DNA by QIAamp DNA minikit (Qiagen) for use in
real-time PCR to determine Plasmodium species and conduct molecular
drug resistance marker analyses.
Dried drug plate coating. Dried drug plates for the P. falciparum ex
vivo drug susceptibility assay were prepared using published methods (14,
18). Briefly, dihydroartemisinin (DHA), artesunate (AS), mefloquine hy-
drochloride (MQ), quinine sulfate hydrate (QN), chloroquine diphos-
phate (CQ), lumefantrine (LUM), piperaquine phosphate (PPQ), and
atovaquone (ATQ) were coated onto 96-well plates. Threefold serial drug
dilutions were performed on plates to reach final concentrations (after
200 l of sample added) ranging from 0.027 to 20 ng/ml for DHA and AS,
0.274 to 200 ng/ml for MQ, 1.71 to 1250 ng/ml for QN, 2.74 to 2,000
ng/ml for CQ, 0.07 to 50 ng/ml for LUM, 0.86 to 625 ng/ml for PPQ, and
0.14 to 100 ng/ml for ATQ. The top row of each plate served as a drug-free
control. Drug plates were dried overnight in a running biosafety cabinet
and stored at 4°C up to 8 weeks prior to use. As a quality control for dried
drug plate integrity, a subset of plates not used in the assays was tested to
ensure an acceptable range of 50% inhibitory concentrations (IC50s) was
attained against the P. falciparum W2 reference clone, as described previ-
ously (14, 18).
HRP-2 ELISA drug susceptibility testing. Blood samples identified by
microscopy as having P. falciparum monoinfections underwent ex vivo
drug susceptibility testing in the histidine-rich protein-2 enzyme-linked
immunosorbent assay (HRP-2 ELISA) as previously described (14). Sam-
ples with a parasitemia of 0.5% were adjusted to 1.5% hematocrit in
0.5% AlbuMAX RPMI, whereas those with 0.5% parasitemia were di-
luted to the parasitemia range of 0.2 to 0.5% by adding 50% hematocrit
human O red blood cells in 10% serum–RPMI 1640 and adjusted to
1.5% hematocrit in 0.5% AlbuMAX RPMI 1640 prior to adding to dried
drug-coated plates. Parasites then were incubated for 72 h at 37°C in a
candle jar, after which plates were frozen and later thawed for analysis of
growth inhibition using the HRP-2 ELISA. Similar methods were used to
conduct susceptibility testing using the control reference clone P. falcipa-
rum W2, by which synchronized cultures with 90% ring forms were
diluted to 0.5% parasitemia and adjusted to 1.5% hematocrit in 0.5%
AlbuMAX RPMI 1640 prior to plating, followed by incubation at 37°C
with mixed gas (5% CO2, 5% O2, and 90% N2). Parasite growth after 72 h
was assessed by HRP-2 ELISA. HRP-2 optical density (OD) readings were
plotted against drug concentrations, and IC50s were estimated by nonlin-
ear regression analysis using the ICEstimator (19, 20) and GraphPad
Prism version 6.0 programs. Samples having poor growth rate, as dis-
cerned by obtaining an OD ratio of 1.7 between the no-drug test wells
and the maximum tested drug concentration, were excluded from data
analysis. A successful IC50 assay result for each P. falciparum clinical iso-
late was defined as achieving a sigmoidal concentration-response with an
IC50 confidence interval ratio of 5 when testing eight serial drug dilu-
tions for at least one of the tested drugs.
Real-time PCR species correction. PCR was used to determine the
infective malaria species for each sample; in cases where microscopy and
PCR diagnoses differed, PCR findings determined the final outcome.
Real-time PCR targeting the parasite’s small subunit rRNA (ssrRNA) gene
was performed on an ABI 7500 machine (Applied Biosystems, War-
rington, United Kingdom) using primer and probe sets to detect Plasmo-
dium genus, P. falciparum, and P. vivax DNA (see Table S1 in the supple-
mental material). Reactions were run in duplicate using a 22-l PCR
mixture containing 3 l of DNA template, 200 nM forward and reverse
primer, 100 nM probe, 1 U of AmpliTaq gold (Applied Biosystems, War-
rington, United Kingdom), and 6 or 5 mM MgCl2 (for detection of genus
and P. vivax or P. falciparum infections, respectively) in 10 buffer A
(Applied Biosystems, Warrington, United Kingdom). Reactions were
started at 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and 60°C
(genus and P. vivax) or 59°C (P. falciparum) for 30 s. Every run included at
least one reaction mixture without DNA as a negative control. The results
were classified as positive if the cycle threshold (CT) value was 35. Sam-
ples were identified as P. falciparum or P. vivax monoinfections if positive
results were obtained from the genus together with either P. falciparum or
P. vivax reactions, respectively. Positive results obtained from all 3 reac-
tions indicated mixed-species infection.
Drug resistance genotyping. We used TaqMan real-time PCR meth-
ods as previously described (21–24), using an ABI 7500 machine (Applied
Biosystems, Warrington, United Kingdom), to evaluate P. falciparum
multidrug resistance gene 1 (Pfmdr1) copy number and single-nucleotide
polymorphisms (SNPs) at codon positions 86, 184, 1034, and 1042 and to
conduct P. falciparum chloroquine resistance transporter gene (Pfcrt)
haplotyping to detect variants of alleles 72 to 76. A PCR restriction frag-
ment length polymorphism method (25) was used to screen samples for
the Pfmdr1 SNP at codon 1246. Mutations in the propeller domain of
the P. falciparum kelch13 (Pfkelch13) gene were analyzed as markers of
artemisinin resistance at the University of North Carolina and University
of Maryland using direct DNA sequencing and Illumina whole-genome
sequencing by following published methods (26–28). Kelch13 (K13) se-
quences were aligned to PF3D7_1343700 (www.plasmodb.org) and
scored for polymorphisms. All genotyping assays included a no-template
negative control and P. falciparum reference DNA for 3D7, Dd2, 7G8,
and W2 clones (Malaria Research & Reference Reagent Resource, Manas-
sas, VA).
Antimalarial activity of patient plasma in an ex vivo bioassay.
Plasma was prepared from blood collected on the screening day for eval-
uation in the P. falciparum ex vivo bioassay to identify study volunteers
likely to have recently taken malaria drugs by following published meth-
ods (29, 30). The antimalarial activity of plasma was measured against the
P. falciparum W2 clone and expressed in units of activity equivalent to
DHA concentration based on a DHA standard curve. The lower limit of
quantification (LLOQ) of the assay is equivalent to 8.8 nM DHA. Plasma
samples were classified as positive for antimalarial activity; thus, patients
were suspected of having taken antimalarials previously if bioassay results
showed DHA equivalent activities of 17.6 nM (higher than 2 LLOQ).
Statistical analysis. Statistical analysis was performed using Graph-
Pad Prism version 6.0 (GraphPad Software, Inc., San Diego, CA, USA).
Parasite susceptibility to each test drug was expressed as the geometric
mean (GM) IC50s for all isolates. The difference of IC50s between groups
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was determined by nonparametric Kruskal-Wallis or Mann-Whitney
tests, as appropriate. Correlations in susceptibility among drugs were
compared using Spearman’s correlation. Kruskal-Wallis or Mann-Whit-
ney tests also were used to analyze for other quantitative variables,
whereas 2 and Fisher’s exact test were used for categorical analyses. Sta-
tistical significance was defined as a P value of 0.05. Bonferroni correc-
tion was applied for Pfmdr1 and Pfkelch13 association analyses with the
IC50.
RESULTS
Plasmodium falciparum isolate sampling and diagnosis. From
2008 to 2013, a total of 753 P. falciparum isolates were collected
from malaria patients at representative sites in Cambodia (Fig. 1).
Northern provinces (Preah Vihear and Oddar Mean Chey) ac-
counted for more than half the total collected (402 isolates), with
western provinces (Pailin and Battambang) accounting for
roughly a third (236) and southern provinces (Kampong Speu,
Preah Sihanouk, Kampot, and Koh Kong) accounting for 15%
(115) (Fig. 1). A diagnostic discordance for detection of Plasmo-
dium species between microscopy and real-time PCR methods
was noted in some cases, with microscopy misclassifying 5.8% (43
out of 741 samples evaluable by PCR) of mixed P. falciparum-P.
vivax infections as monoinfections (Table 1).
Demographic and clinical data, parasitological parameters,
and malaria history. Data on malaria patient demographics, clin-
ical findings, parasitological parameters, and malaria drug use his-
tory were collected to link patient parameters with P. falciparum
drug resistance trends found by region (Tables 2 and 3). The ma-
jority of volunteers were 18 to 29 years old (53.9%) and male
(	85%). Mean body mass index (BMI) was 20.5 kg. Most partic-
ipants were recruited into malaria studies after presenting to a
government clinic or screened for febrile illness by a malaria out-
reach team, with the majority employed in agriculture (70%) and
13% being military personnel. The most common symptoms
at presentation were fever (97.5%), headache (93.6%), chills
(70.8%), myalgia (60.4%), and fatigue (49.5%), and only 3 were
asymptomatic (0.8%). Patients from southern provinces had
lower mean parasite densities at presentation (Table 2) and a
higher proportion with 1 or more infections in the past year (77%)
(Table 3). The proportion found to have gametocytemia at pre-
sentation was low (18%) and was similar among the three regions.
Based on malaria history reported by patients, most reported on-
set of illness 1 to 3 days before presentation, although nearly a
quarter (27.5%) waited more than 3 days to seek treatment (Table
3). More than half reported at least one prior malaria episode in
the past year with 14% reporting 3 or more, with a third reporting
treatment in the past 3 months. Nearly a third of patients could
not recall what antimalarials they used to treat prior infections,
and they could not reliably recall which malaria species they were
treated for. Artesunate-mefloquine was reported to be taken by
42%, chloroquine by 14%, and DHA-piperaquine by 8%. A small
proportion reported using AS monotherapy (4.8%) and quinine-
tetracycline (1.2%), the current third-line agent in Cambodia (Ta-
ble 3).
Ex vivo drug susceptibility of P. falciparum isolates. Ex vivo
drug susceptibility of fresh isolates from 695 P. falciparum
monoinfections was evaluated by HRP-2 ELISA, with 617 total
samples yielding IC50 results, an 88.8% assay success rate. In view-
ing the geometric mean (GM) IC50 data for all drugs by year (Fig.
2), PPQ and MQ showed the most noticeable changes in suscep-
tibility, with a significant decrease in PPQ susceptibility and con-
comitant contrasting increase in MQ sensitivity occurring during
2012 to 2013. Relative to the artemisinin- and mefloquine-sensi-
tive W2 reference clone, isolates had reduced sensitivity to MQ in
the west and south but progressively increased MQ susceptibility
in the north between 2009 and 2013 (Fig. 3). There was modestly
reduced DHA and AS susceptibility, which did not change sub-
stantially over the 5-year period. Overall, there were positive cor-
relations between IC50s for AS and DHA (Spearman 
  0.80, P 
0.001); MQ, LUM, and QN (Spearman 
  0.59 to 0.74, P 
0.001); QN and CQ (Spearman 
  0.49, P  0.001); and CQ and
PPQ (Spearman 
  0.43, P  0.001).
When data were stratified by region, significant trends in ex
vivo drug susceptibilities were observed over the study period (Fig.
3; also see Table S2 in the supplemental material). Of note, PPQ
susceptibility in northern isolates decreased significantly over
time, with GM IC50s (range) in 2010 at 12.8 nM (18.3 to 45.8 nM)
progressively rising to 29.6 nM (4.4 to 150.1 nM) in 2013 (P 
0.001 by Kruskal-Wallis test). In parallel during the same 3-year
period, a contrasting significant trend of increasing MQ suscepti-
bility was found in northern isolates, as indicated by GM IC50s
declining from 67.1 to 26.0 nM (P  0.001 by Kruskal-Wallis test).
Isolates from western Cambodia appeared to show declining sus-
ceptibility to DHA, AS, and CQ from 2008 to 2010, followed in
2011 by increased sensitivity (P  0.001 for DHA, P  0.003 for
AS, and P  0.042 for CQ, all by Kruskal-Wallis test). There also
were significant differences in IC50s for some drugs among regions
within the same collection year. Western Cambodian isolates
from 2010 had significantly higher IC50s for DHA, AS, and CQ
than northern isolates. IC50s for PPQ were significantly greater in
northern than southern isolates in 2012.
Pfmdr1, Pfcrt, and Pfkelch13 drug resistance markers. P. fal-
ciparum monoinfections and mixed P. falciparum/P. vivax infec-
tions were evaluated for Pfmdr1 copy number and SNPs as mo-
lecular markers of drug resistance associated with clinical failures
of MQ, QN, and other common antimalarials. Multiple Pfmdr1
copies were found in nearly a third of evaluable cases (209/644),
and SNP analysis revealed the Y184F mutation was predominant
by far, occurring in 87% (588/676) of evaluable samples, while
only one other SNP (N1042D) was observed in only 0.6% (4/675)
of samples. Southern Cambodia had the highest frequency of iso-
lates with multiple Pfmdr1 copies, whereas northern provinces
during 2009 to 2013 had declining cases of Pfmdr1 amplification,
from 40% to 12% (Fig. 4A), along with Y184F mutation occur-
rence rising significantly from 87% to 100% (P  0.017 and 0.039,
respectively, by 2 test). Molecular analysis of CQ resistance indi-
TABLE 1 Species diagnosis comparison between microscopy and real-
time PCR
Microscopy
Real-time PCR species correctiona
P. falciparum
P. falciparum/
P. vivax P. vivax Total
P. falciparum 647 36 0 683
P. falciparum/P. vivax
mixed infection
0 51 0 51
P. vivax 0 7 0 7
Total 647 94 0 741
a Discordant results between microscopy and PCR are boldfaced.
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cated 100% prevalence (in 689 evaluable isolates) of the CVIET
mutant haplotype at Pfcrt codons 72 to 76.
In analyzing isolates for Pfkelch13 mutations associated with
artemisinin resistance, the mutations were found in 84% of evalu-
able samples (405/482), while 16% of isolates were considered
wild type. C580Y was most prevalent and was found in 66%,
whereas R539T accounted for 15% and Y493H, N458Y, and
G449A occurred at lower frequencies of 2.5%, 1.0%, and 0.2%,
respectively. There was a progressive rise in incidence of K13 mu-
tations, growing to nearly 100% of northern isolates having
C580Y or R539T SNPs in 2012 and 2013 (Fig. 4B). R539T was
most common in northern Cambodia, where a significant rise in
R539T occurrence from 10% to greater than 30% was noted dur-
ing 2009 to 2013 (P  0.003 by 2 test). A trend in increasing
incidence of C580Y was found in western provinces during the
study period (Fig. 4B).
Correlations between ex vivo drug susceptibility and Pfmdr1
or Pfkelch13 genotype. Significant associations were found be-
tween ex vivo drug susceptibilities and the Pfmdr1 or Pfkelch13
genotype in P. falciparum monoinfections. Increasing Pfmdr1
copy number was associated with reduced susceptibility to MQ
and LUM, with GM IC50s for MQ at 45.1, 86.5, 113.3, and 96.0 nM
TABLE 2 Demographic and clinical data and parasitological parameters by region
Parameter
Value by region
West (n  236) North (n  402) South (n  115) Total (n  753)
Gender (no. [%])
Male 185 (78.4) 350 (87.1) 101 (87.8) 636 (84.5)
Female 51 (21.6) 52 (12.9) 14 (12.2) 117 (15.5)
Age (no. [%])
13–17 yr 9 (3.8) 13 (3.2) 9 (7.8) 31 (4.1)
18–29 yr 142 (60.2) 200 (49.8) 64 (55.7) 406 (53.9)
30–39 yr 34 (14.4) 106 (26.4) 20 (17.4) 160 (21.3)
40–49 yr 29 (12.3) 63 (15.7) 17 (14.8) 109 (14.5)
50–65 yr 22 (9.3) 20 (5.0) 5 (4.3) 47 (6.2)
BMI
BMI (means  SD) 19.9  2.24 20.8  2.26 20.3  2.61 20.5  2.34
BMI  18.5 (no. [%]) 45 (19.1) 46 (11.4) 22 (19.1) 113 (15.0)
Normal BMI (no. [%]) 178 (75.4) 327 (81.3) 85 (73.9) 590 (78.4)
BMI  24 (no. [%]) 13 (5.5) 29 (7.2) 8 (7.0) 50 (6.6)
Occupation (no. [%])
Farmer 201 (85.2) 235 (58.5) 89 (77.4) 525 (69.7)
Military 11 (4.7) 87 (21.6) 1 (0.9) 99 (13.1)
Civil/government 3 (1.3) 41 (10.2) 1 (0.9) 45 (6.0)
Laborer 4 (1.7) 11 (2.7) 8 (7.0) 23 (3.1)
Student 14 (5.9) 6 (1.5) 6 (5.2) 26 (3.5)
Housewife 0 12 (3.0) 0 12 (1.6)
Asymptomatic (no. [%]) 0 3 (0.8) 0 3 (0.4)
Symptomatic (no. [%]) 236 (100) 399 (99.2) 115 (100) 750 (99.6)
Fevera 236 (100) 388 (96.5) 110 (95.7) 734 (97.5)
Headache 226 (95.8) 373 (92.8) 106 (92.2) 705 (93.6)
Chillsa 201 (85.2) 252 (62.7) 80 (69.6) 533 (70.8)
Muscle achea 175 (74.2) 217 (54.0) 63 (54.8) 455 (60.4)
Fatiguea 183 (77.5) 175 (43.5) 15 (13.0) 373 (49.5)
Dizzinessa 154 (65.3) 169 (42.0) 25 (21.7) 348 (46.2)
Anorexiaa 151 (64.0) 75 (18.7) 14 (12.2) 240 (31.9)
Nauseaa 135 (57.2) 81 (20.2) 13 (11.3) 229 (30.4)
Abdominal paina 122 (51.7) 98 (24.4) 10 (8.7) 230 (30.5)
Tinnitusa 93 (39.4) 57 (14.2) 9 (7.8) 159 (21.1)
Vomiting 60 (25.4) 60 (14.9) 37 (32.2) 157 (20.9)
Cougha 78 (33.1) 58 (14.4) 11 (9.6) 147 (19.5)
Parasitemia
Asexual (no./l; means  SD) 36,127  53,376b 35,444  54,682 22,306  34,694 33,651  51,871
Gametocyte (no./l; means  SD) 212  176 467  1,363 297  837 379  1,083
Gametocyte negative (no. [%]) 204 (86.4) 321 (79.9) 93 (80.9) 618 (82.1)
Gametocyte positive (no. [%]) 32 (13.6) 81 (20.0) 22 (19.1) 135 (17.9)
a Symptoms were more common in western Cambodia than in other regions (P  0.05 by 2 test).
b Asexual parasite density was highest in the west (P  0.023 by Kruskal-Wallis test).
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and for LUM at 6.0, 10.8, 20.2, and 15.7 nM in isolates with 1, 2, 3,
and 3 copies, respectively (P  0.001 by Kruskal-Wallis test).
There were significantly higher GM IC50s for DHA, AS, MQ, QN,
LUM, and ATQ in isolates with multiple versus single Pfmdr1
copies (Table 4), and the significant association remained for AS,
MQ, QN, and LUM after Bonferroni correction for multiple test-
ing of 8 drugs (P  0.006 [the P value cutoff is adjusted to 0.006 by
dividing typical threshold of 0.05 by 8]). This was greatest for MQ
and LUM, which showed 2-fold higher IC50s in multiple-copy
isolates. In contrast, PPQ and CQ activity were significantly re-
duced in isolates with a single copy of Pfmdr1 (Table 4). No asso-
ciation of Y184F mutation was detected for any drugs tested after
Bonferroni correction (Table 4). Pfkelch13 R539T mutation was
associated with increased IC50s for MQ and ATQ but reduced
IC50s for CQ (Table 4).
Preexisting antimalarial activity and reported malaria his-
tory. A total of 18.3% of 613 patient plasma samples evaluated
against the P. falciparum W2 clone at study enrollment had signif-
icant antimalarial activity (17.6 nM DHA equivalents), while
81.7% of evaluable samples were considered negative (17.6
nM). Results were measured in DHA activity equivalents ranging
as high as 2,547.46 nM in the 1.5% of cases that had extremely high
preexisting activity (250 nM), suggesting recent malaria drug
use, while median activity of all samples was 9.34 nM DHA equiv-
alents (interquartile range [IQR] of 0 to 14.4 nM). Among the
negative samples, 47.3% had activity below or equal to the LLOQ
(8.8 nM), and 34.4% had activity equivalent to background lev-
els (8.8 to 17.6 nM). The proportion of plasma samples positive
for activity was greatest in patients who reported more recent drug
administration in the prior year and rose with increasing numbers
TABLE 3 Patient-reported malaria history by region
Patient-reported parameter
No. (%) of patients by region
West (n  236) Northa (n  292) South (n  115) Total (n  643)
No. of days postonset of illness
1 8 (3.4) 10 (3.4) 1 (0.9) 19 (3.0)
2 75 (31.8) 104 (35.6) 46 (40.0) 225 (35.0)
3 94 (39.8) 85 (29.1) 43 (37.4) 222 (34.5)
3 59 (25.0) 93 (31.8) 25 (21.7) 177 (27.5)
No. of malaria episodes in past yearb
0 157 (66.5) 118 (40.4) 26 (22.6) 301 (46.8)
1c 79 (33.5) 174 (59.6) 89 (77.4) 342 (53.2)
1 44 (18.6) 76 (26.0) 27 (23.5) 147 (22.9)
2 20 (8.5) 45 (15.4) 42 (36.5) 107 (16.6)
3 11 (4.7) 22 (7.5) 7 (6.1) 40 (6.2)
3 4 (1.7) 31 (10.6) 13 (11.3) 48 (7.5)
Timing of last malaria drug administration
14–30 daysd 9 (3.8) 37 (12.7) 5 (4.3) 51 (7.9)
1–3 mod 31 (13.1) 85 (29.1) 48 (41.7) 164 (25.5)
3–6 mo 17 (7.2) 29 (9.9) 21 (18.3) 67 (10.4)
6–12 mo 14 (5.9) 27 (9.2) 14 (12.2) 55 (8.6)
1 yr 38 (16.1) 74 (25.3) 18 (15.7) 130 (20.2)
Never 26 (11.0) 39 (13.4) 8 (7.0) 73 (11.4)
Unsure 101 (15.7) 1 (0.3) 1 (0.9) 103 (16.0)
Drugs taken in past year n  71 n  178 n  88 n  337
Artesunate plus mefloquine 24 (33.8) 78 (43.8) 39 (44.3) 141 (41.8)
Chloroquine 10 (14.1) 25 (14.0) 13 (14.8) 48 (14.2)
DHA plus piperaquinee 11 (15.5) 12 (6.7) 4 (4.6) 27 (8.0)
Monoartesunate 5 (7.0) 11 (6.2) 0 (0.0) 16 (4.8)
Quinine plus tetracycline 1 (1.4) 3 (1.7) 0 (0.0) 4 (1.2)
Unknown antimalarial 24 (33.3) 52 (28.3) 32 (36.0) 108 (31.3)
a Patient-reported malaria history is not available in 2012 to 2013 for the north.
b Malaria episodes are based on patient-reported history of being given a medical diagnosis of malaria.
c Proportion of patients with at least one malaria episode in southern Cambodia is significantly higher than those in northern and western regions (P  0.001 by 2 test).
d Proportion of patients with history of antimalarial drugs used within last 3 months is significantly higher in the south and north than in the west (P  0.001 by 2 test).
e DHA plus piperaquine was most prevalent in the west (P  0.019 by 2 test).
FIG 2 Overall trends in ex vivo drug susceptibility of P. falciparum isolates
collected during 2008 to 2013 in Cambodia. GM IC50s (in nanomolars) are
shown for each drug by year.
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of reported malaria episodes (P  0.005 by 2 test) (Fig. 5). Bio-
assay activity levels trended with patient-reported antimalarial use
history, with higher median activity observed in patients reporting
recent drug use relative to those reporting less recent or no drug
use (Fig. 5).
Isolates from patients with positive bioassay activity sug-
gesting recent malaria drug use showed poor assay success rates
for measuring ex vivo drug susceptibility and had a higher in-
cidence of drug resistance markers relative to bioassay-negative
cases. The presence of preexisting antimalarial activity in pa-
tient plasma appeared to contribute to greater incidence of
HRP-2 assay failures, with IC50s being unattainable in samples
having 250 nM DHA equivalents, while there was 80% and
90% assay success in samples with activity above background
FIG 3 Ex vivo drug susceptibility of P. falciparum isolates from Cambodia by year and region. Box-whisker plots of IC50s (in nanomolars) are shown for each drug
stratified by collection year and region: west (gray), north (pink), and south (green). Dashed lines denote median IC50s against the P. falciparum W2 reference
clone and interquartile ranges. Significant P values by Mann-Whitney U test indicate differences in IC50s between regions within the same year. A significant
progressive decline in MQ IC50s and rise in PPQ IC50s during 2009 to 2013 in northern isolates is denoted by an asterisk (P  0.001 by Kruskal-Wallis test).
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and without significant bioassay activity, respectively. In the
18% of bioassay-positive cases (n  105), plasma activity was
substantially higher in samples failing to yield HRP-2 ELISA
IC50s (median, 121.1 nM) compared with successful HRP-2
assay IC50 determination (44.4 nM).
There were very weak correlations between IC50s for AS and
DHA, which declined as preexisting antimalarial activity in-
creased (Spearman 
  0.2, P  0.001), and for MQ, which
increased with increasing activity (Spearman 
  0.1, P  0.018),
and none for other drugs (data not shown). There were slight
increases in CQ IC50s observed in samples with preexisting anti-
malarial activity in plasma, with GM IC50s to CQ being 156.8,
140.4, and 179.2 nM for below LLOQ, background, and positive
antimalarial activity in plasma, respectively (P  0.011 by
Kruskal-Wallis test).
Differences in Pfmdr1 genotype distribution were noted in bio-
assay-positive versus -negative cases, as suggested by isolates with
multiple Pfmdr1 copies plus the Y184F mutation occurring more
frequently in patients with preexisting antimalarial activity
(43.3%) than those without (25.7%), while wild-type isolates (sin-
gle copy and 184Y) were more common in patients with bioassay-
negative (12.7%) versus bioassay-positive (6.7%) activity. Similarly,
FIG 4 Frequency of Pfmdr1 amplification and Kelch13 propeller mutations
by region and year. Isolate collection regions are indicated by colored bars as
western (gray), northern (pink), and southern (green) Cambodia. Numbers of
isolates analyzed for each region/year are indicated above each bar graph.
Significant P values are shown for differences in frequency of Pfmdr1 amplifi-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4638 aac.asm.org August 2015 Volume 59 Number 8Antimicrobial Agents and Chemotherapy
the Pfkelch13 R539T mutation was more prevalent in patients with
preexisting antimalarial activity (22%) than those without (7%),
while no difference was observed for C580Y (Table 5).
DISCUSSION
We conducted an extensive investigation into ex vivo drug suscep-
tibility and molecular drug resistance marker profiling of a large
set of P. falciparum isolates (n  753 total) from western, north-
ern, and southern Cambodia during 2008 to 2013 in patients at
high occupational risk for exposure (31). Resistance to PPQ ap-
pears to be emerging in northern Cambodia, as evidenced by geo-
metric mean IC50s more than doubling over a relatively short 3
years from 2010 to 2013, during which there was a contrasting
increase in susceptibility to MQ following reduced MQ pressure.
There was a corresponding decrease in Pfmdr1 copy number as-
sociated with reduced PPQ in vitro susceptibility as piperaquine
drug pressure increased. Chloroquine resistance based on Pfcrt
mutations appears to have been at or near fixation in this popula-
tion of isolates. Moreover, mutations in the propeller domain of
the P. falciparum Pfkelch13 gene associated with artemisinin resis-
tance were common among isolates (84%) and near fixation in
isolates from northern Cambodia. We found trends in patient
demographics and malaria history, as well as correlations between
patient-reported malaria drug use and ex vivo bioassay of plasma
antimalarial activity, suggesting strong in vivo drug pressure is
driving multidrug resistance emergence. Overall, our results sup-
port the utility of ex vivo drug susceptibility testing and genotyp-
ing to track drug resistance for informing Cambodian national
malaria drug policy decisions. Declining PPQ susceptibility in
northern Cambodia is of particular concern and, in conjunction
with recent findings of clinical treatment failures with DHA-PPQ,
indicates the urgency of fielding alternative antimalarials to ad-
dress this growing public health crisis.
The temporal and regional IC50 trends with a corresponding
decline in Pfmdr1 copy number appeared to coincide with policy
changes replacing AS-MQ as the first-line ACT with DHA-PPQ.
Western isolates collected during 2009 to 2011 following replace-
ment of AS-MQ with DHA-PPQ in 2008 had a lower frequency of
Pfmdr1 amplification, a molecular marker of clinical resistance to
MQ (21, 32), than isolates from northern Cambodia, where DHA-
PPQ became the first-line agent in 2012. IC50 trends in northern
Cambodia from 2010 to 2013 revealed a decline in MQ IC50s and
Pfmdr1 copy number with a corresponding rise in PPQ IC50s.
Southern isolates had a contrasting trend of elevated MQ IC50s,
lower PPQ IC50s, and a significantly higher frequency of Pfmdr1
amplification relative to those of other regions, consistent with a
previous study in the southern province of Kampot (33) reporting
an association between increased MQ IC50s and Pfmdr1 amplifi-
cation with clinical AS-MQ failures. While artemisinin IC50s ap-
peared to remain relatively stable throughout most of Cambodia
during the study, the prevalence of mutations in the Kelch13 pro-
peller domain having known associations with artemisinin resis-
tance progressively increased in western and northern isolates in
recent years. The alarming rise in PPQ IC50s in northern Cambo-
dia and growing prevalence of Pfkelch13 mutations suggests
emerging PPQ resistance and increasing artemisinin resistance.
The association between multiple Pfmdr1 copies and signifi-
cantly increased IC50s for MQ, QN, DHA, and AS has been found
in other recent ex vivo drug sensitivity studies in Cambodia (34).
However, sampling over a longer period (2010 to 2013), we cap-
tured a significant progressive increase in PPQ IC50s not previ-
ously detected and representing a 3-fold rise over values we re-
ported earlier for isolates from western Cambodian in 2006 to
FIG 5 Associations between percent plasma samples positive for ex vivo antimalarial activity and patient-reported history of malaria episodes and treatment. P
values of 2 association tests are noted. Dotted lines indicate median DHA equivalents, in nanomolars, for bioassay-positive patients in each self-reported
category. Numbers of isolates analyzed for each category are indicated above each bar graph.
TABLE 5 Pfmdr1 and Pfkelch13 genotype distribution in patients






1 copy (WT) 316 (69.0) 55 (49.5) 0.001
1.5 copies 142 (31.0) 56 (50.5)
Pfmdr1 Y184F
WT 74 (15.9) 13 (12.4) 0.367
184F 392 (84.1) 92 (87.6)
Pfmdr1 copy, Y184Fa
1 copy, Y 54 (12.7) 7 (6.7) 0.001
1 copy, F 247 (58.1) 46 (44.2)
1.5 copies, Y 15 (3.5) 6 (5.8)
1.5 copies, F 109 (25.7) 45 (43.3)
Pfkelch13
WT 68 (24.6) 11 (15.1) 0.001
539T 20 (7.3) 16 (21.9)
580Y 188 (68.1) 46 (63.0)
a Parasites were classified into four groups based on Pfmdr1 copy number and mutation
at Y184F.
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2007 (14), prior to the introduction of DHA-PPQ. Interestingly,
some patients in 2013 appeared to harbor highly resistant PPQ
infections, as 5% of isolates evaluated in the HRP-2 assay failed to
yield IC50 results, since they were capable of growing in the pres-
ence of the maximal PPQ concentration tested (674 nM). Consis-
tent with rising PPQ IC50s noted here, we recently reported rapid
progression of clinical DHA-PPQ failure for the treatment of un-
complicated P. falciparum between two studies conducted in 2010
and 2013 in northern Cambodia (9, 35). A 36% clinical failure rate
was associated with patient PPQ plasma levels in the terminal
elimination phase falling below PPQ IC50s, suggesting rapidly
emerging piperaquine resistance on top of existing artemisinin
resistance as the likely culprit. Our findings of progressively in-
creasing PPQ IC50s and DHA-PPQ treatment failures in northern
Cambodia in recent years suggest that PPQ resistance is emerging
in the north, especially since earlier trials conducted by others in
2010 found clinical DHA-PPQ failures in western Cambodia
(25% in Pailin and 10.7% in Pursat), while DHA-PPQ remained
100% effective in northern and eastern Cambodia (7).
Selective drug pressure studies in laboratory clones suggest
PPQ resistance is not mediated by Pfmdr1 copy number variation
but is associated with amplification of a neighboring upstream
region on chromosome 5 as well as a novel SNP in Pfcrt (36).
However, consistent with recent clinical evidence, we found re-
duced PPQ susceptibility in isolates with single Pfmdr1 copies. In
isolates from western Cambodia in Pursat (2011 to 2012), chro-
mosome 5 copy number variations were found (34), and addi-
tional clinical studies in Cambodia during 2008 to 2010 uncovered
association between Pfmdr1 single-copy isolates and DHA-PPQ
treatment failures (7). Likewise, Pfmdr1 amplification was associ-
ated with reduced susceptibility to MQ, LUM, and QN but in-
creased susceptibility to PPQ and CQ in isolates from western
Thailand where PPQ use is rare, although the chromosome 5 copy
number variation was not seen (37, 38). Evidence of association
between Pfmdr1 deamplification and elevated PPQ IC50 in clinical
isolates may reflect emerging piperaquine resistance following a
shift in drug pressure away from mefloquine, which had driven
Pfmdr1 amplification.
The Pfcrt CVIET mutant haplotype, associated with reduced
sensitivity of in vitro clones to CQ and PPQ (39), appears to have
reached fixation in Cambodia, as reported in earlier studies on
Thai and Cambodian isolates (40). However, we cannot rule out
the possibility that samples uninterpretable in our assay repre-
sented haplotypes other than those we screened for, i.e., wild-type
CVMNK, CVIET, and SVMNT. Similarly, China-Myanmar bor-
der isolates with a single Pfmdr1 copy and the Pfcrt K76T genotype
were reported to have reduced CQ and PPQ susceptibility (38).
While there appears to be a link between PPQ and CQ resistance,
PPQ may have additional resistance mechanisms suggested by
preserved activity against CQ-resistant isolates from Africa (41,
42) and lack of correlation between Pfcrt polymorphisms and re-
duced PPQ susceptibility in isolates from various regions (43, 44).
Our findings support the notion that until definitive molecular
markers of PPQ clinical resistance are identified, the combination
of Pfmdr1 deamplification and PPQ IC50s is useful for tracking
what appears to be rapidly emerging PPQ resistance.
It remains unclear whether growing reports of DHA-PPQ
treatment failures in Cambodia are the result of emerging resis-
tance to artemisinins, PPQ, or both components. While ex vivo
PPQ IC50s appear to be at least partially predictive of DHA-PPQ
treatment failure, the contribution of resistance to the artemisinin
component based on IC50s alone is less clear. Nationwide during
our 5-year study, artemisinin susceptibility remained relatively
constant. However, the lack of correlation between in vitro arte-
misinin drug susceptibility and molecular findings suggests that it
is helpful to include assays in addition to HRP-2 ELISA as useful
indicators of drug susceptibility changes as part of future efforts.
In our prior AS monotherapy trials, elevated artemisinin IC50 re-
sults in the HRP-2 assay were associated with prolonged parasite
clearance times (45, 46) but not clinical failure. Recently, a ring-
stage survival assay (RSA) measuring the survival rate of isolates
grown in the presence of DHA has been shown to be more predic-
tive of delayed in vivo parasite clearance (47).
Pfkelch13 propeller domain mutant alleles have been identified
as artemisinin resistance markers, associated with in vitro evidence
of artemisinin resistance in the RSA and delayed in vivo parasite
clearance in Cambodian patients administered ACT (26, 48).
Here, molecular analysis of western and northern Cambodian iso-
lates indicated a progressive rise in incidence of K13 mutations,
growing to nearly 100% of isolates having C580Y or R539T SNPs
in recent years. The predominant K13 mutation found in our
study population was C580Y, the major mutation observed in
southeast Asian isolates, which also was found associated with
delayed parasite clearance with ACT therapy in patients from
Cambodia and mainland southeast Asia (26, 48, 49). Our results
showed no correlation between K13 mutations and IC50s for ar-
temisinins, consistent with previous studies reporting poor corre-
lation between artemisinin IC50s and in vivo parasite clearance and
in vitro ring survival rate (47). To date, the contribution of K13
mutations in conferring resistance to other drugs has not been
reported. Although we observed a statistically significant associa-
tion between K13 mutations and elevated IC50s for MQ, ATQ, and
CQ, the biological significance remains unclear. In the case of
ATQ in particular, all isolates tested were ATQ sensitive with an
IC50 of 30 nM, much lower than the resistance threshold of
1,500 nM. A recent investigation into the role of K13 mutations in
conferring artemisinin resistance conducted using zinc finger nu-
clease-targeted genetic engineering of Pfkelch13 demonstrated
that K13 mutations confer higher levels of artemisinin resistance
in vitro in recent Cambodian isolates than reference lines, suggest-
ing that a combined contribution of K13 mutations with other
recently acquired mutations (perhaps those associated with part-
ner drug resistance) exacerbates artemisinin resistance (50). One
such resistance mechanism to consider in conjunction with K13
mutations is Pfmdr1 amplification, which was involved in confer-
ring artemisinin resistance derived in vitro (51) and was shown in
our study population isolates to be associated with significantly
elevated artemisinin IC50s. This idea of combined mutations re-
sulting in artemisinin resistance is further supported by recent
findings from a large GWAS study of southeast Asian isolates sug-
gesting that polymorphisms in genes linked to drug resistance,
including Pfcrt and Pfmdr2, provide a genetic background en-
couraging the emergence of K13 mutations linked to regional ar-
temisinin resistance (49).
Growing reports of DHA-PPQ clinical treatment failures in
Cambodia (7–10, 35) impart urgency in identifying an effective
alternative first-line ACT to help mitigate malaria morbidity and
mortality in southeast Asia. Results here are intended to support
Cambodian public health officials in updating national malaria
treatment guidelines to identify an appropriate first-line ACT to
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replace DHA-PPQ. Tracking changes in ex vivo parasite drug
susceptibilities and known markers of resistance, such as
Pfmdr1 and K13 propeller mutations, will help to better under-
stand the relative contributions that the artemisinins and var-
ious partner drugs (MQ, PPQ, and other future partners) play
in conferring resistance. As we demonstrate here, however, re-
sults of field isolate assays should be interpreted cautiously.
When we evaluated patient specimens for preexisting antima-
larial activity, although there was little direct correlation with
the IC50, we found preexisting antimalarial activity not only
was common but often was associated with poor parasite
growth ex vivo that prevented determination of IC50 drug sus-
ceptibility. In addition, patients with preexisting antimalarial
activity were more likely to be infected with isolates having
Pfmdr1 amplification and the Y184F mutation or K13 muta-
tions, but these isolates did not always yield IC50 susceptibility
results. Thus, we may be underestimating the true burden of
resistance when relying on ex vivo drug susceptibility assays
alone in the absence of molecular marker analysis. This also
raises important implications for enrollment criteria in malaria
drug trials; while it is tempting to exclude subjects reporting
recent drug use, not only is such use sometimes concealed
but also we may be missing the highest-risk populations by
doing so.
Specific recommendations based on our findings here and in
recent drug therapy trials indicate that a switch of therapy for
uncomplicated P. falciparum away from DHA-PPQ on the Thai-
Cambodian border is needed. That being said, there are few obvi-
ous alternatives. One possibility being considered by public health
officials is the short-term reintroduction of AS-MQ, perhaps al-
ternating with DHA-PPQ, given an apparent inverse relationship
in Pfmdr1 amplification in response to drug pressure from these
two partner drugs. Others have found Pfmdr1 amplification to be
a robust indicator of MQ resistance (34), and this should be used
to monitor for reemergence of MQ resistance. Atovaquone-
proguanil was used in Pailin province starting in 2009 as part of a
World Health Organization multidrug-resistant malaria contain-
ment effort (52), and it has been shown to be effective, particularly
in combination with artesunate (53). However, ATQ clinical re-
sistance can develop rapidly via point mutations in the malaria
parasite mitochondrial cytochrome b gene (54). We found little
evidence here for ATQ resistance in northern isolates in 2013, as
indicated by single-digit nanomolar IC50s comparable to values
reported in Thai isolates from 1998 to 2005 lacking cytochrome b
gene codon 268 mutations (55). An ACT with a novel partner drug
class, artesunate-pyronaridine (Pyramax) (56, 57), recently has
become available in Cambodia. While this class purportedly lacks
cross-resistance with current drugs in use, a subgroup analysis of
patients treated along the western Cambodia border during a
phase 3 European Medicines Agency licensure study indicated
efficacy below 90% in 2007 and parasite clearance times signifi-
cantly longer than those at other sites (58). There have been addi-
tional concerns with artesunate-pyronaridine regarding hepatic
toxicity (59) and embryotoxicity (60), as well as the potential for
cross-resistance to PPQ (61). In the absence of clear alternatives to
currently available first-line therapies, intensive monitoring of
drug resistance profiles is indicated, and ex vivo drug susceptibility
testing combined with molecular marker analysis is an effective
means for achieving this important objective.
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